about
Clinical guide to fertility preservation in hematopoietic cell transplant recipientsHaematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009.Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia.Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses.Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMTPhysician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipientsDefining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Development and evaluation of a specifically designed website for haematopoietic stem cell transplant patients in Leeds.Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT.Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation.Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.Central venous catheter placement: extending the role of the nurse.Mesna therapy and hypertension.Characteristics of monoclonal immunoglobulins that interfere with serum inorganic phosphate measurement.The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study.Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.Distinctive features of immunoglobulin heavy chain variable region gene rearrangement in multiple myeloma.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.Guideline for the diagnosis and management of myelofibrosis.Psychosocial supportive care services for haematopoietic stem cell transplant patients; a service evaluation of three UK transplant centres.Report on slide session, British Society for Haematology, 42nd annual scientific meeting, Brighton, 2002.The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.Micromegakaryocytes in CSF.Observation-based early warning scores to detect impending critical illness predict in-hospital and overall survival in patients undergoing allogeneic stem cell transplantation.Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.Single step enrichment of blood dendritic cells by positive immunoselectionEffect of Campath-1H antibody on human hematopoietic progenitors in vitroSystemic toxoplasmosis post allogeneic stem cell transplantation (Allo-SCT): lessons learned from HIV?Taking the measure of alemtuzumabPrognostic impact of serum ferritin concentration on survival following reduced-intensity conditioned allogeneic haemopoietic SCTMeasurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working PCorrection: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patientsReducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization InitiativeAllogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT
P50
Q33809651-8F00007C-68DC-4FB8-95E5-E91CDB10D3F8Q34245639-1335F72E-7DB1-4347-B159-01EF5A4197B4Q34474785-8382F1FD-EF3A-4261-B5FB-6EDB37A4A851Q35105465-0CEA725F-0347-4F25-A5D8-6A6B94330F3EQ35834633-51BB1324-01E1-42B0-AA2C-49EC53915A69Q37104278-74C792B3-CA04-4C6D-A32D-DE5C2A813055Q37556136-03D91E52-0626-4E6B-949B-9D2C10520FDFQ37598758-1E701661-30E0-4E43-B291-7F8726AE4DACQ37904672-2840DE8F-5BEB-48D9-9FF4-5E3B460BFBE9Q38561684-AA37DB2E-E401-457C-B933-095D33132B6CQ38933848-F5B95BC6-5C9F-48A8-8785-A739317EA3D3Q39251542-F9EC267D-7A70-4A7A-AC8E-9C7F0501D602Q40721939-C521B7F2-01B3-4A87-98E9-1E4EF06EE993Q43488186-8DF72E0C-5247-450E-8457-A228C2182087Q43698524-7A1ED6B7-9CEF-468D-A361-5027FDC4985AQ45809767-C6702FE5-9FE1-42A3-8E4B-336E16A2000EQ47562374-911E5ED0-DEE8-4E8E-8897-3415146B02B8Q47581987-9B9F30F6-AAB3-4884-8AA4-2F094F94F5C9Q47865904-0D97B49D-F159-4DCF-A631-7C09DA063EB1Q48081430-0C3AF820-9C69-4240-826B-F2C2B6CF06F8Q48251584-77B0AC51-7B2A-486B-85B6-43172A381760Q48660711-EB09A1A6-0117-44DB-8DA5-FBAC46BF748EQ50453985-648E4FEE-970B-4375-BC0F-688374371CBFQ50495964-74E2D1BF-F7A2-4DA4-844E-CBB22770DDF3Q50672020-29306315-C60C-4552-874D-D1B256EDAC0EQ50723421-2E640D23-BD88-4B62-9866-BE746B37FA38Q51804258-CE81D089-DFCE-432B-90AE-03773789F0FDQ52838715-F03B4861-B4B8-4091-8F04-60EFF3D0FC9BQ52846211-E78B4C2A-3ED8-4182-BDAB-81F5006BB844Q52853939-45212EA5-252F-4871-B063-0D63BBEE12F8Q54495485-266F37B4-B3BC-4C0C-B847-CF1F1D920518Q57607832-6B394CBD-A320-4DB6-8317-900B1B9F9971Q72088966-14E6EEA2-A5E2-4910-AC55-34B2B391C755Q80502499-5FFC5288-5359-4A18-BF21-9B782835F403Q80843156-92B588E0-A48B-41FF-891B-47D7830B899EQ83071659-0F7938B0-E8EE-4892-B147-4DEC8C82A982Q89452353-0EC5C4D3-7213-49FA-95AD-4B86EE6FB9E6Q90119037-07D533D2-E423-43DA-BF3A-3E8E3E889F83Q90634045-2555221C-032A-4823-BADB-2742EA0598BCQ92296737-24408A61-8FFE-4CE8-A161-F3692C0CA678
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
M Gilleece
@ast
M Gilleece
@en
M Gilleece
@es
M Gilleece
@nl
type
label
M Gilleece
@ast
M Gilleece
@en
M Gilleece
@es
M Gilleece
@nl
prefLabel
M Gilleece
@ast
M Gilleece
@en
M Gilleece
@es
M Gilleece
@nl
P106
P1153
6603562039
P31
P496
0000-0003-0364-3573